以硼替佐米为主的化疗方案治疗多发性骨髓瘤的疗效和不良反应

Clinical efficacy and adverse reactions of bortezomib-based chemotherapy in the treatment of multiple myeloma

目的探讨以硼替佐米为主的化疗方案应用于多发性骨髓瘤(MM)治疗中的临床价值。方法选取2015年12月至2018年11月45例MM患者作为研究对象,利用随机数字表法分为研究组(n=23)与对照组(n=22),对照组MM患者予以VAD化疗方案治疗,研究组MM患者予以硼替佐米联合VAD化疗方案治疗。比较两组的治疗总有效率。结果研究组MM患者临床治疗总有效率(78.26%,18/23)高于对照组(63.64%,14/22),差异有统计学意义(P<0.05)。结论应用VAD化疗方案联合硼替佐米对MM治疗有效性较优。

Objective To investigate the clinical value of bortezomib-based chemotherapy in the treatment of multiple myeloma(MM).Methods Forty-five patients with MM from December 2015 to November 2018 were selected as the study subjects. The patients were divided into the study group(n=23) and the control group(n=22) by random number table. The patients in the control group were treated with VAD chemotherapy regimen. The patients in the study group were treated with bortezomib combined with VAD chemotherapy regimen. The total effective rates were compared between the two groups.Results The total effective rate was significantly higher in the study group(78.26%,18/23) than that in the control group(63.64%,14/22), the difference was significant(P<0.05). Conclusions The application of VAD chemotherapy combined with bortezomib is more effective on MM.